Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Inhaled Nitric Oxide Market, by Application
1.4.2 LAMEA Inhaled Nitric Oxide Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market - Global
Chapter 4. LAMEA Inhaled Nitric Oxide Market by Application
4.1 LAMEA Neonatal Respiratory Treatment Repellent Market by Country
4.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country
4.3 LAMEA Acute Respiratory Distress Syndrome (ARDS) Market by Country
4.4 LAMEA Other Applications Market by Country
Chapter 5. LAMEA Inhaled Nitric Oxide Market by Country
5.1 Brazil Inhaled Nitric Oxide Market
5.1.1 Brazil Inhaled Nitric Oxide Market by Application
5.2 Argentina Inhaled Nitric Oxide Market
5.2.1 Argentina Inhaled Nitric Oxide Market by Application
5.3 UAE Inhaled Nitric Oxide Market
5.3.1 UAE Inhaled Nitric Oxide Market by Application
5.4 Saudi Arabia Inhaled Nitric Oxide Market
5.4.1 Saudi Arabia Inhaled Nitric Oxide Market by Application
5.5 South Africa Inhaled Nitric Oxide Market
5.5.1 South Africa Inhaled Nitric Oxide Market by Application
5.6 Nigeria Inhaled Nitric Oxide Market
5.6.1 Nigeria Inhaled Nitric Oxide Market by Application
5.7 Rest of LAMEA Inhaled Nitric Oxide Market
5.7.1 Rest of LAMEA Inhaled Nitric Oxide Market by Application
Chapter 6. Company Profiles
6.1 Getinge AB
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Merck Group
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Halma PLC
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Linde PLC (Praxair, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Acquisition and Mergers:
6.5 Air Liquide S.A.
6.5.1 Company Overview
6.5.1 Financial Analysis
6.6 Beyond Air, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expense
6.6.4 Recent strategies and developments:
6.6.4.1 Trials and Approvals:
6.7 Mallinckrodt PLC (International Minerals and Chemical Corporation)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Trials and Approvals:
6.7.5.2 Partnerships, Collaborations, and Agreements:
6.8 VERO Biotech LLC
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Trials and Approvals:
6.9 Nu-Med Plus, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.10. Novoteris, LLC
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Trials and Approvals:
Unique Offerings 
